Comorbid LUTS and erectile dysfunction: Optimizing their management

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2497-2506

  Kaminetsky, Jed C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Reductase inhibitors; Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms; Sexual dysfunction; 1 Adrenergic receptor antagonists

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL; CHOLESTENONE 5ALPHA REDUCTASE; CYCLIC GMP PHOSPHODIESTERASE; PDE5A PROTEIN, HUMAN; PHOSPHODIESTERASE V;

ALLERGIC REACTION; ASTHENIA; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC TEST; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPOTENSION; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; META ANALYSIS; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SOMNOLENCE; SYSTEMATIC REVIEW; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG COMBINATION; MALE; PATHOPHYSIOLOGY; QUALITY OF LIFE; SEXUAL BEHAVIOR; URINATION DISORDERS;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ADRENERGIC ALPHA-ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SEXUAL BEHAVIOR; URINATION DISORDERS;

EID: 33846009780     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X154141     Document Type: Review

References (76)

1. Hoesl CE, Woll EM, Burkart M, Altwein JE. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005;47:511-17
2. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47:824-37
3. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
4. Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int 2002;89:208-13
5. Vallancien G, Emberton M, Harving N, et al.; for the Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003;169:2257-61
6. Braun MH, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical 'aging male' symptoms? Results of the 'Cologne Male Survey.' Eur Urol 2003;44:588-94
7. Nicolosi A, Glasser DB, Moreira ED, et al.; Erectile Dysfunction Epidemiology Cross National Study Group. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res 2003;15:253-7
8. Ponholzer A, Temml C, Obermayr R, et al. Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004;64:772-6
9. Shin R, Häkkinen JT, Hakama M, et al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 2005;174:205-9
10. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey.' Int J Impot Res 2000;12:305-11
11. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urology 2000;163:460-3
12. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44
13. Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ 2001;323:1042-6
14. Narayan P, Indudhara R. Pharmacotherapy for benign prostatic hyperplasia. West J Med 1994;161:495-506
15. Cassel CK, ed. Geriatric Medicine: An Evidence-based Approach, 4th edn. New York: Springer-Verlag, 2003
16. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9
17. Garraway W, Russell EBAW, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Practice 1993;43:318-21
18. Schiff JD, Mulhall JP. The link between LUTS and ED: clinical and basic science evidence. J Androl 2004;25:470-8
19. Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998;51:428-36
20. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4
21. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-8
22. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-62
23. Esposito K, Giugliano F, Martedi E, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005;28:1201-3
24. Azadzoi KM, Master TA, Siroky MB. Effect of chronic ischemia on constitutive and inducible nitric oxide synthase expression in erectile tissue. J Androl 2004;25:382-8
25. Lepor H, Tang R, Kobayashi S, et al. Localization of the alpha 1A-adrenoceptor in the human prostate. J Urol 1995;154:2096-9
26. Levin RM, Wein AJ. Adrenergic alpha receptors outnumber beta receptors in human penile corpus cavernosum. Invest Urol 1980;18:225-6
27. Buzelin JM, Fonteyne E, Kontturi M, et al; The European Tamsulosin Study Group. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:597-605
28. Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adrenergic receptors in erectile function. Int J Impot Res 2000;12(Suppl 1):S48-63
29. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004;5:251-7
30. Fawcett L, Baxendale R, Stacey P, et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A 2000;97:3702-7
31. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838-45
32. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006;3:676-81
33. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170:530-47
34. Stage AC, Hairston JC. Symptom scores: mumbo jumbo or meaningful measures? Curr Urol Rep 2005;6:251-6
35. O'leary MP. Treatment and pharmacologic management of BPH in the context of common comorbidities. Am J Manag Care 2006;12(5 Suppl):S129-40
36. Rosen RC, Capelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-26
37. Cappelleri JC, Siegel RL, Glasser DB, et al. Relationship between patient self-assessment and erectile dysfunction and the sexual health inventory for men. Clin Ther 2001;23:1701-19
38. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006;28:13-25
39. Ansong KS, Lewis C, Jenkins P, Bell J. Help-seeking decisions among men with impotence. Urology 1998;52:834-7
40. Schou J, Holm NR, Meyhoff HH. Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1996;179:119-22
41. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398-405
42. Furuya S, Kumamoto Y, Yokoyama E, et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982;128:836-9
43. Flomax [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2005
44. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994;113:723-8
45. 1-adrenoceptor antagonists. Eur Urol 2001;40(Suppl 4):5-11
46. Kaplan SA, Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology 2006;67:225-31
47. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994;44:46-51
48. Höfner K, Claes H, De Reijke TM, et al; for the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-41
49. Food and Drug Administration. ALFOTAM trial. Center for Drug Administration and Research. Available at: www. pbm.va.gov/criteria/Alpha- Blocker%20CFU%207-2005.pdf [Accessed 11 May 2006]
50. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin l0mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92:257-61
51. Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med 2006;166:565-71
52. Yassin A, Saad F, Hoesl CE, et al. Alpha-adrenoreceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS - implications for clinical practice. Andrologia 2006;38:1-12
53. Cialis [package insert]. Indianapolis, IN: Lilly ICOS LLC, 2005
54. Levitra [package insert]. West Haven, CT: Bayer Pharmaceutical Corporation, 2005
55. Viagra [package insert]. New York, NY: Pfizer, Inc, 2005
56. Auerbach SM, Gittelman M, Mazzu A, et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004;64:998-1003
57. 1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006;67:1199-204
58. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172:1935-40
59. Narayan P, Gagnier P, Doyle C. Concomitant use of sildenafil with tamsulosin or terazosin - a retrospective safety evaluation. J Urol 2004;171(Suppl):357. Abstract 1356
60. McConnell JD, Roehrborn CG, Bautista OM, et al; for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98
61. Kirby RS, Roehrborn C, Boyle P, et al; PREDICT Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26
62. McConnell JD, Bruskewitz R, Walsh P, et al; for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63
63. Roehrborn CG, Boyle P, Nickel JC, et al; ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41
64. Barkin J, Guimarães M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003;44:461-6
65. Zlotta AR, Giannakopoulos X, Maehlum O, et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003;44:89-93
66. Rosario DJ, Woo H, Potts KL, et al. Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 1997;80:579-86
67. Bruskewitz R, Issa MM, Roehrborn CG, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998;159:1588-94
68. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol 2003;17:103-7
69. Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year follow-up. J Urol 1997;158:1834-8
70. Hoffman RM, MacDonald R, Wilt TJ. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev 2004;(1). Art. No.: CD001987. DOI: 10.1002/14651858. CD001987.pub2.
71. Cerruti G, Tani F. TUIP for infravesically obstructed BPH patients: a review of 300 cases. Arch Esp Urol 1994;47:911-14
72. Riehmann M, Knes JM, Heisey D, et al. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995;45:768-75
73. Te AE, Malloy TR, Stein BS, et al. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int 2006;97:1229-33
74. Bachmann A, Schurch L, Ruszat R, et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol 2005;48:965-71
75. Hammadeh MY, Madaan S, Hines J, et al. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology 2003;61:1166-71
76. Wasson JH, Reda DJ, Bruskewitz RC, et al; The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995;332:75-9